Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Blank, M.
Right arrow Articles by Shoenfeld, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blank, M.
Right arrow Articles by Shoenfeld, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 11, No. 12, 1917-1926, December 1999
© 1999 Japanese Society for Immunology

Characteristics and pathogenic role of anti-ß2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome

Miri Blank1, Ari Waisman2, Edna Mozes2, Takao Koike3 and Yehuda Shoenfeld1

1 Research Unit of Autoimmune Diseases, Department of Medicine `B', Sheba Medical Center, Tel-Hashomer 52621, Israel, affiliated to Sackler Faculty of Medicine, Tel-Aviv University.
2 Department of Immunology, The Weizmann Institute of Sciences, Rehovot 76100, Israel
3 Department of Medicine II, Hokkaido University School of Medicine, Sapporo 060, Japan

Correspondence to: Y. Shoenfeld, Department of Medicine `B', Sheba Medical Center, Tel-Hashomer 52621, Israel

Antiphospholipid syndrome is characterized by the presence of high titers of anti-ß2-glycoprotein I (ß2GPI) antibodies, lupus anticoagulant associated with thromboembolic phenomena, thrombocytopenia and recurrent fetal loss. Single-chain Fv (scFv) were prepared from four anti-ß2GPI mAb, CAM, CAL, CAR and 2C4C2, and one anti-ssDNA. All five scFv showed the same antigen binding properties as the original mAb. Replacement of the pathogenic CAM VH domain with the non-pathogenic CAL VH or anti-ssDNA VH decreased the binding affinity of the scFv to ß2GPI and completely abrogated the anticoagulant activity. Exchanging the CAM VH with anti-DNA VH resulted in a shift from anti-ß2GPI to anti-ssDNA binding of the scFv. Replacement of the CAM VL with CAL VL did not affect the binding and activity. BALB/c mice were immunized with the anti-ß2GPI scFv, and the scFv resulting from the substitution of the heavy (H) and light (L) chains. The mice which were immunized with CAM, 2C4C2 and CAR scFv developed clinical manifestations of experimental anti-phospholipid syndrome. Elevated titers of mouse anti-cardiolipin (aCL), anti-ß2GPI, associated with lupus anticoagulant activity, thrombocytopenia, prolonged activated partial thromboplastin time and a high percentage of fetal resorptions were detected, in the CAM scFv group and in the scFv composed of CAM VH groups. High titers of aCL, anti-ß2GPI, anti-ss/dsDNA and anti-histone associated with lupus findings were observed in the sera of the 2C4C2 scFv-immunized mice. Immunization with CAL scFv did not lead to any clinical findings. The current study shows that scFv of pathogenic antibodies are capable of inducing the same clinical manifestations as the whole antibody molecule upon active immunization. Replacement of H/L chains point to the importance of the VH domains in the pathogenic potential of anti-ß2GPI.

Keywords: anti-ß2-glycoprotein I, anti-cardiolipin antibodies, anti-phospholipid syndrome, single-chain Fv, autoimmunity

Transmitting editor: G. Klein


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
S CUCNIK, B BOZIC, T KVEDER, M TOMSIC, and B ROZMAN
Avidity of Anti-{beta}2-Glycoprotein I and Thrombosis or Pregnancy Loss in Patients with Antiphospholipid Syndrome
Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. B. de Laat, R. H.W.M. Derksen, R. T. Urbanus, M. Roest, and P. G. de Groot
{beta}2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome
Blood, December 1, 2004; 104(12): 3598 - 3602.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
Y Shoenfeld and M Blank
Autoantibodies associated with reproductive failure
Lupus, September 1, 2004; 13(9): 643 - 648.
[Abstract] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.